Evidence map›Paper›PMID 28865367›Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2017

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.

Renata Salgado Fernandes, Carolina de Aguiar Ferreira, Daniel Cristian Ferreira Soares, Anna Margherita Maffione, Danyelle M Townsend, Domenico Rubello, André Luís Branco de Barros

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Added value of 3'-deoxy-3'-[Annals of medicine · 2025
    Pooled it
  2. Review
  3. Review
  4. Clinical value of 3'-deoxy-3'-[Insights into imaging · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Renata Salgado FernandesLaboratório de radioisótopos, Departamento de análises Clinicas, Universidade Federal de Minas Gerais (UFMG), Avenida Presidente Antônio Carlos, 6627, Belo Horizonte, Minas Gerais, Brazil.
Carolina de Aguiar FerreiraDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Daniel Cristian Ferreira SoaresLaboratório de Bioengenharia, Universidade Federal de Itajubá (UNIFEI), Rua Irmã Ivone Drumond, 200, Itabira, Minas Gerais, Brazil.
Anna Margherita MaffioneDepartment of Nuclear Medicine, Radiology, Medical Physics and Clinical Pathology, Santa Maria della Misericordia Hospital, Rovigo, Italy.
Danyelle M TownsendDepartment of Drug Discovery and Pharmaceutical Sciences, Medical University of South Carolina, USA.
Domenico RubelloDepartment of Nuclear Medicine, Radiology, Medical Physics and Clinical Pathology, Santa Maria della Misericordia Hospital, Rovigo, Italy. Electronic address: domenico.rubello@libero.it.
André Luís Branco de BarrosLaboratório de radioisótopos, Departamento de análises Clinicas, Universidade Federal de Minas Gerais (UFMG), Avenida Presidente Antônio Carlos, 6627, Belo Horizonte, Minas Gerais, Brazil. Electronic address: brancodebarros@yahoo.com.br.

Funding

SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2012 to 2020
$20.2M
NIGMS NIH HHS P20 GM103542
6 · The paper itself

Abstract

Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.

Indexed as

AnimalsAntineoplastic AgentsDiagnostic ImagingHumansNeoplasmsRadiopharmaceuticalsTreatment OutcomeAntineoplastic AgentsRadiopharmaceuticalsAnti-tumor efficacyRadiolabeled probesTherapeutic monitoringTherapy response

Identifiers

PMID28865367
PMCPMC6361128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.